Objectives To study the clinical phenotypes, determined based on cumulative disease activity manifestations, and sociodemographic factors associated with depression and anxiety in SLE. Methods Patients attending a single centre were assessed for depression and anxiety. SLE clinical phenotypes were based on the organ systems of cumulative 10-year SLE Disease Activity Index 2000 (SLEDAI-2K), prior to visit. Multivariable logistic regression analyses for depression, anxiety, and coexisting anxiety and depression were performed to study associated SLE clinical phenotypes and other factors. Results Among 341 patients, the prevalence of anxiety and depression was 34% and 27%, respectively, while 21% had coexisting anxiety and depression. Patients with skin involvement had significantly higher likelihood of anxiety compared with patients with no skin involvement [adjusted odds ratio (aOR) = 1.8; 95% CI: 1.1, 3.0]. Patients with skin involvement also had higher likelihood of having coexisting anxiety and depression (aOR = 2.0, 95% CI: 1.2, 3.9). Patients with musculoskeletal (MSK) (aOR = 1.9; 95% CI: 1.1, 3.5) and skin system (aOR = 1.8; 95% CI: 1.04, 3.2) involvement had higher likelihood of depression compared with patients without skin or musculoskeletal involvement. Employment status and fibromyalgia at the time of the visit, and inception status were significantly associated with anxiety, depression, and coexisting anxiety and depression, respectively. Conclusion SLE clinical phenotypes, specifically skin or MSK systems, along with fibromyalgia, employment and shorter disease duration were associated with anxiety or depression. Routine patient screening, especially among patients with shorter disease duration, for these associations may facilitate the diagnosis of these mental health disorders, and allow for more timely diagnosis.
BackgroundIn our recent systematic review, we have shown a high prevalence for depression [35% (95% CI: 29.9%-40.3%)] and anxiety [25.8% (95% CI: 19.2%-32.9%)] in Systemic Lupus Erythematosus (SLE)1. A better understanding of the SLE phenotypic manifestations associated with depression and anxiety may lead to enhanced early diagnosis and treatment strategies.ObjectivesTo determine the overall prevalence of anxiety and depression in a cohort of SLE patients, stratified by SLE-implicated organ systems and to study their correlates.MethodsPatients attending the Toronto Lupus Clinic from August 2017 to January 2019 were studied. Depression and Anxiety were diagnosed with Center for Epidemiological Studies-Depression Scale (CES-D; cut-off≥26), BECK Depression Inventory-II (BDI-II; cut-off≥18), and the BECK Anxiety Inventory (BAI; cut-off≥19). Disease activity was measured with the SLEDAI-2k (SLE Disease Activity Index 2000). The SLE phenotypic manifestations were stratified based on the organ systems of cumulative 10-year SLEDAI-2K – skin, musculoskeletal (MSK), ocular, neuropsychiatric, and internal organ manifestations (including renal, pulmonary, immunologic, and hematologic). Separate univariate and multivariate logistic regression analyses (for depression [D], anxiety [A], and anxiety and depression [AD]) were performed to study the factors associated with A, D, and AD, including age at enrollment, sex, ethnicity, disease duration, inception status (enrolled in the clinic within 1 year of SLE diagnosis), fibromyalgia, and SLE phenotypic manifestations, comparing their significance to the group with neither A or D.Results341 patients (89.7% female), with mean age 45.9±17.8 years were studied. The prevalence of anxiety and depression in the cohort was 34% and 27% respectively, while 21% of the total cohort was found to have both anxiety and depression. Among the 3 outcome groups (A, D, and AD), MSK system involvement has a significantly higher prevalence when compared to the group with neither A or D (p-values<0.05). Concurrently, skin system involvement was also significantly more prevalent among A, D, and AD groups, in comparison to the normal group (p-values<0.05). Patients with anxiety had significantly higher odds of skin system involvement compared to the normal group (OR=1.81; 95% CI: 1.09, 3.01). Also, patients with depression had higher odds of MSK (OR=1.94; 95% CI: 1.07, 3.50) and skin system involvement (OR=1.79; 95% CI: 1.00, 3.20) compared to the group with neither A or D. Additionally, the odds of skin system involvement was significantly higher among patients with both A and D, compared to the group with neither (OR=2.02, 95% CI: 1.05, 3.88). In all three models (A, D, and AD), employment and fibromyalgia were also significant (p-values<0.05). Age at enrolment was significant in the D and AD models (p-value<0.05), while inception patient status [inception had a mean disease duration at study visit of 12.1±11.4 years compared to non-inception 19.6±10.6 years] was significant in the D model exclusively ...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.